Patients who received thrombolytic therapy for acute myocardial infarc
tion in a large international trial were divided into two groups on th
e basis of age; those less than or equal to 40 years (n=269) and those
>40 years (n=7787). The younger group included more men (89.9% vs 75.
9%, P=0.009) and fewer patients had a history of coronary artery disea
se, hypertension, and diabetes mellitus. A family history of cardiovas
cular disease was significantly more prevalent among the young patient
s (53.4% vs 41.9%, P=0.0002). Significantly more younger patients than
older patients were smokers at the time of infarction (76.2% vs 42.9%
, P<0.0001) and the average number of cigarettes smoked per day was al
so significantly higher in younger patients (27.8 +/- 14.3 vs 19.9 +/-
12.9, P<0.01). Younger patients had a better outcome, with lower. rat
es of cardiogenic shock (1.1% vs 7.0%, P=0.0002), stroke (0.0% vs 1.9%
, P=0.02) and haemorrhage (1.9% vs 5.9%, P=0.006), as well as a better
Killip class at discharge (Killip >1 in 4.5% vs 8.0%, P<0.001), and l
ower hospital and 6-month mortality (0.7% and 3.1% vs 8.3% and 12%, P<
0.001, respectively). The better outcome of younger patients with acut
e myocardial infarction is related to their better baseline characteri
stics. Young patients with acute myocardial infarction have a strong f
amily history of cardiovascular disease and a high prevalence of smoki
ng. Smoking is the most important modifiable risk factor in these pati
ents